A Multicentre, Long-term Safety, Efficacy, and Pharmacokinetics Study of Lubiprostone in Paediatric Subjects Aged ≥ 6 Years to < 18 Years With Functional Constipation.
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 24 Jul 2017
At a glance
- Drugs Lubiprostone (Primary)
- Indications Constipation
- Focus Adverse reactions; Therapeutic Use
- Sponsors Sucampo Pharmaceuticals
- 23 Jul 2017 This study has been completed in Poland (End date:2017-05-01).
- 06 Oct 2016 Status changed from recruiting to active, no longer recruiting.
- 02 Nov 2015 Planned End Date changed from 1 Dec 2016 to 1 Aug 2017 as reported by ClinicalTrials.gov record.